TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Trial of Gemcitabine/Cisplatin Versus S-1/Cisplatin in Advanced Biliary Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age : older than 20~* Eastern Cooperative Oncology Group (ECOG) performance status 0 -2~* Histologically confirmed adenocarcinoma of the biliary tract~* Metastatic or unresectable biliary cancer~* No prior chemotherapy for biliary cancer~* A patient with at least one measurable primary lesion of which the diameter is confirmed to be 10mm in Spiral CT or multidetector CT (MD CT)~* Adequate bone marrow, liver, renal function~Exclusion Criteria:~* A patient with no measurable disease~* A patient who received previous palliative chemotherapy for biliary cancer~* A patient who received adjuvant chemotherapy for biliary cancer within 1year~* A patient with previous active or passive immunotherapy.~* A pregnant or lactating patient

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gemcitabine/Cisplatin (Type: EXPERIMENTAL): None
- S-1/Cisplatin (Type: EXPERIMENTAL): D1-14 S-1 40mg/m2 po bid D1,D8 Cisplatin 25/m2 + N/S 150cc miv over 60mins Repeated every 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy and Safety of Alemtuzumab in Auotoimmune Cytopenias

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients must have a diagnosis of the following autoimmune cytopenias:~   immune thromobocytopenia purpura (ITP) autoimmune hemolytic anemia (AIHA) autoimmune neutropenia (AIN) pure red cell aplasia (PRCA) and~2. Patients must have refractory disease according to the following criteria~   1. not respond to steroids or~  2. need prednisolone more than 15 mg/d for maintenance therapy~3. Complete work up for baseline evaluation and measurement~4. Age \> 18 years~5. Patient's free written inform consent~Exclusion Criteria:~1. Patients with a known hypersensitivity to murine proteins or to any component of alemtuzumab~2. Patients with poor performance status (ECOG criteria of 3-4)~3. Serologic evidence of human immunodeficiency virus exposure~4. Patients with active uncontrolled infection. Patients that are HIV positive or test positive on HBs or HCV antigens.~5. Pregnant or lactating women~6. Serious medical or psychiatric illness which prevent informed consent~7. Patients who are likely to lost to follow up (eg, unwilling or difficult to return, cannot be contacted)~8. Patients with active malignancies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Clinical Follow-up of the Echo Bi-Metric Microplasty Stem for Total Hip Arthroplasty

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects are eligible for this trial if they satisfy all of the following criteria:~  * Patient is 18 to 65 years of age, inclusive~ * Patient is skeletally mature~ * Patient qualifies for primary unilateral or bilateral total hip arthroplasty based on physical exam and medical history including at least one of the following:~ * Osteoarthritis~ * Avascular necrosis~ * Rheumatoid arthritis~ * Correction of functional deformity~ * Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable by other techniques~ * Patient has no history of previous total hip arthroplasty or arthrodesis of the affected hip joint(s)~ * Patient is willing and able to complete scheduled follow-up evaluations as described in the Informed Consent~ * Patient, or the patient's legally authorized representative, has participated in the Informed Consent process and is willing and able to sign an IRB- approved informed consent~Exclusion Criteria:~* Subjects will be excluded from this trial if they satisfy any of the following criteria as determined by the research staff or in the judgment of the treating physician:~  * Patient has a total prosthetic hip replacement device (including surface replacement arthroplasty, endoprosthesis, etc.) in the affected hip joint(s)~ * Patient is septic or has an active infection~ * Patient is uncooperative patient or is incapable of following directions~ * Patient is diagnosed with osteoporosis~ * Patient is diagnosed with a metabolic disorder which may impair bone formation~ * Patient is diagnosed with osteomalacia~ * Patient has distant foci of infections which may spread to the implant site

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Optimal Handling of Common Bile Duct Calculus, a Prospective Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* cholecystectomy~Exclusion Criteria:~* Ongoing icterus or pancreatitis~* History of anamneses pancreatitis/icterus~* Allergy against x-ray contrast~* Stones more than 6 mm in ductus~* No passage of contrast to duodenum~* malignant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Biliary calculus remain (Type: EXPERIMENTAL): biliary calculus, less than or equal to 6 mm, remains
- Biliary calculus removed (Type: EXPERIMENTAL): biliary calculus, less than or equal to 6 mm, removed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Pre-emptive Cycline Treatment on Cetuximab Induced Skin Toxicity in Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced or metastatic colorectal cancer, histologically confirmed, first or second metastatic line~* K-RAS wild-type~* Adjuvant prior chemotherapy allowed provided that all toxicities are grade \< or = 1 (excepted alopecia and neuropathy)~* Age between 18 and 80 years~* WHO Performance Status \< or = 2~* Complete initial assessment before first treatment administration for imaging and pharmacogenetic, within 15 days for biology, and within 7 days for clinical examination.~* Haematologic and hepatic parameters : neutrophils \> or = 1500 /mm3, platelets \> or = 100000/mm3, Total bilirubin \< or 2 x ULN, AST and ALT \< or = 3 x ULN, APL \< or = 5 x ULN~* Absence of total dihydropyrimidine dehydrogenase deficiency~* Patient able to comply with study requirements~* Signed written informed consent~Exclusion Criteria:~* History or presence of an other cancer, excepted cutaneous cancer (basocellular carcinoma), in situ cancer of the cervix or breast cancer curatively treated~* Any other concomitant anti-cancer therapy~* Prior anti EGFR therapy, anti angiogenic therapy is allowed~* Prior cyclines hypersensitivity~* Treatment with cyclines within 7 days before randomization~* Presence of a rash at randomization time~* Symptomatic or uncontrolled ventral nervous system metastases~* Total dihydropyrimidine dehydrogenase deficiency~* No recovery of any toxicity Grade \< or = 1 related to a past anticancerous treatment excepted for alopecia and neuropathy~* Active inflammatory bowel disease or other bowel~* Significant serious pathology or any unstable medical condition (cardiac pathology uncontrolled, myocardial infarction within 6 months before enrollment, systemic active uncontrolled infection)~* atropine contra-indication~* any investigational agent without marketing authorization within 4 weeks before enrollment~* Patient who is pregnant or breast feeding~* Woman or man of childbearing potential not consenting to use adequate contraceptive precautions during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): Intensified FOLFIRI plus Cetuximab + Doxycycline 100 mg daily per os to start 7 days before Cetuximab for 6 weeks + skin moisturizers (Dexeryl), sun protection.
- Arm B (Type: ACTIVE_COMPARATOR): Intensified FOLFIRI plus Cetuximab + skin moisturizers (Dexeryl), sun protection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Key Inclusion Criteria:~* Have access to the internet and are able to complete online assessments on a computer.~* Have relapsing-remitting MS and satisfy the approved therapeutic indication for DMF per the Canadian Product Monograph.~* Are either treatment-naïve or being treated for RRMS with IFN or GA but, per the Prescribing Physician, have a suboptimal response (e.g., suboptimal efficacy, intolerance, or poor adherence) to IFN or GA or have stopped treatment with IFN or GA for RRMS as a result of suboptimal response within 30-60 days of enrollment.~Key Exclusion Criteria:~* Have major comorbid conditions that would preclude their participation in the study as determined by the Prescribing Physician.~* Have a history of malignancy. (Patients with basal cell carcinoma that has been completely excised prior to study entry remain eligible.)~* Are receiving disease modifying therapies other than IFN or GA or have initiated treatment with a new disease modifying therapy since discontinuation of IFN or GA.~NOTE: Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment naive to dimethyl fumarate (Type: None): Participants who are prescribed dimethyl fumarate as their initial therapy will receive 120 mg tablet administered orally twice a day for 7 days, then switch to maintenance dose of 240 mg tablet twice daily.
- Switch to dimethyl fumarate (Type: None): Participants who are prescribed dimethyl fumarate after suboptimal response to IFN or GA will receive 120 mg tablet administered orally twice a day for 7 days, then switch to maintenance dose of 240 mg tablet twice daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Nicotine for the Prevention of PONV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults (18-80 years)~* ASA I-II, non-smokers (or ex-smokers who have not been smoking for more than 2 years)~* Undergoing elective surgery (ENT, abdominal, urological, gynaecological); and~* Consenting to take part in the study will be included.~Exclusion Criteria:~* Smokers (cigarette, pipe, cigar)~* Patients undergoing nicotine replacement therapy~* Prolonged postoperative intubation~* Postoperative nasogastric tube

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Nicotine patch (Type: EXPERIMENTAL): Nicotinell® Patch 10 cm2, containing 17.5 mg of nicotine, with an average delivery rate of 7 mg of nicotine per 24 hours (= TTS 10)
- Placebo patch (Type: PLACEBO_COMPARATOR): Placebo patch 10 cm2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Combined Anticancer Treatment of Advanced Colon Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Synchronous or metachronous peritoneal carcinomatosis arising from histologically proven colorectal or appendiceal adenocarcinoma~* Complete macroscopic cytoreduction (CCR-0/1)~* Free treatment interval of at least 6 month after the last chemotherapy~* Age over 18 and below 71 years~* Good general health status (Karnofsky \> 70%, ECOG 0-2)~* Absence of hematogenous metastasis (lung, bone, brain, \> 3 peripheric resectable liver metastases)~* Absence of contraindication for systemic chemotherapy and/or extended surgery~* Life expectancy greater than 6 months~* Written informed consent~* Creatinine clearance \> 50 ml/min, serum creatinine ≤ 1.5 x ULN~* Serum bilirubin ≤ 1.5 x ULN (upper limit of normal), ASAT and ALAT ≤ 2.5 x ULN~* Platelet count \> 100,000 /ml, haemoglobin \> 9 g/dl, neutrophile granulocytes ≥ 1,500 /ml, International Normalized Ration (INR) ≤ 2~* Absence of peripheral neuropathy \> grade 1 (CTCAE v4.0)~* No pregnancy or breast feeding. Adequate contraception in fertile patients.~Exclusion Criteria:~* Incomplete cytoreduction~* Hematogenous metastasis including irresectable liver metastasis~* Prior chemotherapy or therapy with EGFR receptor antibody for metastatic disease~* K-ras mutation~* Known allergy to murine or chimeric monoclonal antibodies~* Histology of signet ring carcinoma~* Other malignancy than disease under study / second cancer~* Impaired liver, renal or hematologic function as mentioned above (inclusion criteria)~* Heart failure NYHA ≥ 2 or significant Coronary Artery Disease~* Alcohol and/or drug abuse~* Patients unable or unwilling to comply with the study protocol, treatment or follow-up~* Patients included in other clinical trials interfering with the present study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 71 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): 1. FOLFOX/FOLFIRI + cetuximab (6 cycles)~2. CRS and HIPEC~3. FOLFOX/FOLFIRI + cetuximab (6 cycles)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Colchicine in COVID-19: a Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent for participation in the study~* Virological diagnosis of SARS-CoV-2 infection (real-time PCR)~* Hospitalized due to clinical/instrumental diagnosis of pneumonia~* Oxygen saturation at rest in ambient air ≤94%~* PaO2/FiO2 ratio of 350 to 200~Exclusion Criteria:~* Known hypersensitivity to colchicine or its excipients~* Severe diarrhea~* Patients who cannot take oral therapy~* Pregnant and lactating patients~* Patients with severe cardiac, renal insufficiency (creatinine clearance (CCL) \<30 mL / min)~* Patients with kidney or liver damage \[(AST or ALT\> 5 times the normal limits in International Units (ULN)\]; or are taking CYP3A4 enzyme - P glycoprotein inhibitors.~* Known other clinical condition that contraindicates colchicine and cannot be treated or solved according to the judgement of the clinician~* Neutrophils \<1.000 / mmc~* Platelets \<50.000 / mmc~* Bowel diverticulitis or perforation~* Patients already in ICU or requiring mechanical ventilation~* Patients receiving Tocilizumab~* Patients already enrolled in other clinical trials

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Colchicine plus current care (Type: EXPERIMENTAL): Colchicine 0.5 mg three times a day if weight is less than 100 kg; 1 mg twice a day if weight is more than 100 kg for 30 days or up to discharge. Reduce based on gastrointestinal symptoms appearance at discretion of the Investigator.
- Current care alone (Type: NO_INTERVENTION): Current care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Swedish Rectal Prolapse Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Complete rectal prolapse~2. Informed consent~3. Surgical correction is considered appropriate~4. Capable to participate in follow-up visits and answering questionnaires~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Abdominal suture rectopexy (Type: ACTIVE_COMPARATOR): Patients were randomized first into either an abdominal or a perineal approach. The abdominal group was then further randomized to suture rectopexy or resection rectopexy.
- Abdominal resection rectopexy (Type: ACTIVE_COMPARATOR): Patients were randomized first into either an abdominal or a perineal approach. The abdominal group was then further randomized to suture rectopexy or resection rectopexy.
- Perineal Delorme (Type: ACTIVE_COMPARATOR): Patients were randomized first into either an abdominal or a perineal approach. The perineal group was then further randomized to Delorme's operation or Altemeier's operation.
- Perineal Altemeier (Type: ACTIVE_COMPARATOR): Patients were randomized first into either an abdominal or a perineal approach. The perineal group was then further randomized to Delorme's operation or Altemeier's operation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hydroxychloroquine for COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Age above 18 years~* Women of childbearing age only: Must agree to practice continuous effective contraception for the duration of the study (a method which results in a failure rate less than 1% per year)~* Disease severe enough to require hospitalization~* QTc interval lower than 450 msec~Exclusion Criteria:~* Respiratory rate \>24/min~* Pregnancy (tested with a pregnancy test) or lactation~* Weight \<50 kg~* Hemodynamic/rhythm instability~* Acute myocardial infarction Type 1~* Use of concomitant medications that prolong the QT/QTc interval.~* Any regular concomitant medication which is contraindicated in the use together with HCQ~* Hypersensitivity to Hydroxychloroquine, Chloroquine or other 4-Aminoquinolines~* Pre-existing retinopathy or maculopathy~* Known Glucose-6-phosphate dehydrogenase deficiency (haemolytic anaemia, Favism)~* Haematopoietic systems diseases~* Myasthenia gravis~* Any other significant disease, disorder or finding which, in the opinion of the investigator, may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data~Additionally, clinical evaluation and laboratory values inform eligibility of the patient based on the judgement of the study team. These may include: total bilirubin, transaminase level, albumin concentration, haematological parameters, troponin and BNP levels, creatinine, creatinine kinase levels.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Hydroxychloroquine Sulfate (Type: EXPERIMENTAL): First dose: 800 mg. From 2nd day on, each patient will get 600 mg (3 capsules) once a day until day 7 (6 more does of 600 mg).
- Placebo (Type: PLACEBO_COMPARATOR): Equivalent number of placebo capsules at the day of inclusion (4 capsules) and the following days (3 capsules)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Anticipated Versus Actual Patient and Caregiver Burden Following Ambulatory Orthopedic Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing outpatient arthroscopic knee debridement or meniscectomy surgery~* Age 18-85~* Primary caregiver available during preoperative period who is employed full-time or part-time~* English speaking~* Patients who are employed full-time or part-time~Exclusion Criteria:~* Patients on disability or worker's compensation~* Patients undergoing concurrent procedures~* Patients who are self-employed~* Caregivers who are self-employed~* Surgeons: Dr. Altchek, Dr. Warren, Dr. O'Brien

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Patient/Caregiver Dyad (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues